CY1117394T1 - Λιξισενατιδη για χρηση στην θεραπευτικη αντιμετωπιση της στενωσης ή/και αποφραξης στο συστημα παγκρεατικων πορων - Google Patents
Λιξισενατιδη για χρηση στην θεραπευτικη αντιμετωπιση της στενωσης ή/και αποφραξης στο συστημα παγκρεατικων πορωνInfo
- Publication number
- CY1117394T1 CY1117394T1 CY20161100151T CY161100151T CY1117394T1 CY 1117394 T1 CY1117394 T1 CY 1117394T1 CY 20161100151 T CY20161100151 T CY 20161100151T CY 161100151 T CY161100151 T CY 161100151T CY 1117394 T1 CY1117394 T1 CY 1117394T1
- Authority
- CY
- Cyprus
- Prior art keywords
- pancreatic
- lixisenatide
- blocking
- therapeutic treatment
- resource system
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Solid-Sorbent Or Filter-Aiding Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Η παρούσα εφεύρεση σχετίζεται με μια φαρμακευτική σύνθεση για χρήση στην θεραπευτική αντιμετώπιση μιας ασθένειας ή κατάστασης, όπου η εν λόγω ασθένεια ή κατάσταση είναι σχετιζόμενη με στένωση ή/και απόφραξη ευρισκόμενη στο σύστημα παγκρεατικών πόρων, με την εν λόγω σύνθεση να περιλαμβάνει τουλάχιστον έναν αγωνιστή GLP-1 και βέλτιστα έναν φαρμακευτικά αποδεκτό φορέα, αραιωτικό ή/και βοηθητική ουσία.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP11183867 | 2011-10-04 | ||
EP12766695.6A EP2763690B1 (en) | 2011-10-04 | 2012-10-02 | Lixisenatide for use in the treatment of stenosis or/and obstruction in the pancreatic duct system |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1117394T1 true CY1117394T1 (el) | 2017-04-26 |
Family
ID=46963761
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20161100151T CY1117394T1 (el) | 2011-10-04 | 2016-02-24 | Λιξισενατιδη για χρηση στην θεραπευτικη αντιμετωπιση της στενωσης ή/και αποφραξης στο συστημα παγκρεατικων πορων |
Country Status (11)
Country | Link |
---|---|
US (1) | US20130096060A1 (el) |
EP (1) | EP2763690B1 (el) |
CY (1) | CY1117394T1 (el) |
DK (1) | DK2763690T3 (el) |
ES (1) | ES2562651T3 (el) |
HR (1) | HRP20160171T1 (el) |
HU (1) | HUE028568T2 (el) |
PL (1) | PL2763690T3 (el) |
PT (1) | PT2763690E (el) |
SI (1) | SI2763690T1 (el) |
WO (1) | WO2013050379A1 (el) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX344293B (es) | 2008-10-17 | 2016-12-13 | Sanofi Aventis Deutschland | Combinacion de una insulina y un agonista de glp-1. |
PT2498802E (pt) | 2009-11-13 | 2015-04-13 | Sanofi Aventis Deutschland | Composição farmacêutica que compreende um agonista de glp-1, uma insulina e metionina |
BR112012011403B8 (pt) | 2009-11-13 | 2021-05-25 | Sanofi Aventis Deutschland | composição farmacêutica líquida compreendendo um agonista glp-1 e metionina e uso da mesma |
RU2546520C2 (ru) | 2010-08-30 | 2015-04-10 | Санофи-Авентис Дойчланд Гмбх | Применение ave0010 для производства лекарственного средства для лечения сахарного диабета 2 типа |
US9821032B2 (en) | 2011-05-13 | 2017-11-21 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin |
US9408893B2 (en) | 2011-08-29 | 2016-08-09 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical combination for use in glycemic control in diabetes type 2 patients |
TWI559929B (en) | 2011-09-01 | 2016-12-01 | Sanofi Aventis Deutschland | Pharmaceutical composition for use in the treatment of a neurodegenerative disease |
TWI641381B (zh) | 2013-02-04 | 2018-11-21 | 法商賽諾菲公司 | 胰島素類似物及/或胰島素衍生物之穩定化醫藥調配物 |
CN105899190B (zh) | 2014-01-09 | 2022-06-14 | 赛诺菲 | 门冬胰岛素的稳定化药物制剂 |
WO2015104314A1 (en) | 2014-01-09 | 2015-07-16 | Sanofi | Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives |
SG11201604708VA (en) | 2014-01-09 | 2016-07-28 | Sanofi Sa | Stabilized glycerol free pharmaceutical formulations of insulin analogues and/or insulin derivatives |
LT3229828T (lt) | 2014-12-12 | 2023-06-12 | Sanofi-Aventis Deutschland Gmbh | Insulino glargino/liksisenatido fiksuoto santykio kompozicija |
TWI748945B (zh) | 2015-03-13 | 2021-12-11 | 德商賽諾菲阿凡提斯德意志有限公司 | 第2型糖尿病病患治療 |
TW201705975A (zh) | 2015-03-18 | 2017-02-16 | 賽諾菲阿凡提斯德意志有限公司 | 第2型糖尿病病患之治療 |
WO2022212273A1 (en) * | 2021-03-29 | 2022-10-06 | Sanford Health | Methods and compositions for treating lysosomal storage disorders |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2038597A1 (en) * | 1991-03-19 | 1992-09-20 | Jose P. Garzaran | A method and a pharmaceutical preparation for treating pain |
US5424286A (en) | 1993-05-24 | 1995-06-13 | Eng; John | Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same |
US5595756A (en) * | 1993-12-22 | 1997-01-21 | Inex Pharmaceuticals Corporation | Liposomal compositions for enhanced retention of bioactive agents |
DK0966297T4 (da) | 1996-08-08 | 2013-03-18 | Amylin Pharmaceuticals Llc | Regulering af gastrointestinal motilitet |
PT944648E (pt) | 1996-08-30 | 2007-06-26 | Novo Nordisk As | Derivados do glp-1. |
ATE304864T1 (de) | 1997-01-07 | 2005-10-15 | Amylin Pharmaceuticals Inc | Verwendung von exedinen und deren antagonisten zur verminderung der lebensmittelaufnahme |
NZ502592A (en) | 1997-08-08 | 2002-03-28 | Amylin Pharmaceuticals Inc | Exendin agonist peptides and their use in the treatment of type I and II diabetes |
MXPA00004670A (es) | 1997-11-14 | 2003-07-14 | Amylin Pharmaceuticals Inc | Compuestos agonistas de exendina novedosos. |
ES2297902T5 (es) | 1997-11-14 | 2013-07-09 | Amylin Pharmaceuticals, Inc. | Compuestos novedosos agonistas de exendina |
EP1076066A1 (en) | 1999-07-12 | 2001-02-14 | Zealand Pharmaceuticals A/S | Peptides for lowering blood glucose levels |
ATE432289T1 (de) | 2002-07-04 | 2009-06-15 | Zealand Pharma As | Glp-1 und behandlungsmethode für diabetes |
RU2376314C2 (ru) | 2002-10-02 | 2009-12-20 | Зилэнд Фарма А/С | Стабилизированные соединения эксендина-4 |
EP1937297A2 (en) | 2005-09-08 | 2008-07-02 | Gastrotech Pharma A/S | Use of a glp-1 molecule for treatment of biliary dyskinesia and/or biliary pain/discomfort |
-
2012
- 2012-10-02 WO PCT/EP2012/069485 patent/WO2013050379A1/en active Application Filing
- 2012-10-02 DK DK12766695.6T patent/DK2763690T3/en active
- 2012-10-02 PT PT127666956T patent/PT2763690E/pt unknown
- 2012-10-02 ES ES12766695.6T patent/ES2562651T3/es active Active
- 2012-10-02 US US13/633,563 patent/US20130096060A1/en not_active Abandoned
- 2012-10-02 EP EP12766695.6A patent/EP2763690B1/en not_active Not-in-force
- 2012-10-02 HU HUE12766695A patent/HUE028568T2/en unknown
- 2012-10-02 PL PL12766695T patent/PL2763690T3/pl unknown
- 2012-10-02 SI SI201230454T patent/SI2763690T1/sl unknown
-
2016
- 2016-02-16 HR HRP20160171TT patent/HRP20160171T1/hr unknown
- 2016-02-24 CY CY20161100151T patent/CY1117394T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
SI2763690T1 (sl) | 2016-03-31 |
WO2013050379A1 (en) | 2013-04-11 |
HUE028568T2 (en) | 2016-12-28 |
EP2763690A1 (en) | 2014-08-13 |
HRP20160171T1 (hr) | 2016-03-11 |
EP2763690B1 (en) | 2015-11-25 |
ES2562651T3 (es) | 2016-03-07 |
PL2763690T3 (pl) | 2016-04-29 |
US20130096060A1 (en) | 2013-04-18 |
DK2763690T3 (en) | 2016-02-15 |
PT2763690E (pt) | 2016-03-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1117394T1 (el) | Λιξισενατιδη για χρηση στην θεραπευτικη αντιμετωπιση της στενωσης ή/και αποφραξης στο συστημα παγκρεατικων πορων | |
CY1120297T1 (el) | Ρυθμιστες υποδοχεα ανδρογονου και χρησεις αυτων | |
CY1124407T1 (el) | Ενωσεις αναστολεα αυτοταξινης | |
CY1123810T1 (el) | Τριφθορομεθυλ υποκατεστημενα πυραζολια ως αναστολεις καλλικρεϊνης στο ανθρωπινο πλασμα | |
CY1122966T1 (el) | 5-βρωμο-2,6-δι-(1η-πυραζολ-1-υλ)πυριμιδιν-4-αμινη για χρηση στη θεραπευτικη αγωγη καρκινου | |
CY1121735T1 (el) | 7-benzyλ-10-(2-meθyλobenzyλ)-2,6,7,8,9,10-eξaϋδpoϊmiδazo[1,2-α]πυριδο[4,3-d]πυριμιδιν-5(3η)-ονη για χρηση στην αγωγη του καρκινου | |
CY1116424T1 (el) | Παραγωγο αδενινης ως αναστολεας ρι3κ | |
CY1118695T1 (el) | Αναστολεις απομεθυλασων ιστονων | |
CY1124078T1 (el) | Συνθεσεις που περιλαμβανουν αναστολεα λυσινης ειδικης απομεθυλασης-1 που εχει δακτυλιο πυριμιδινης και χρηση αυτων στη θεραπεια καρκινου | |
BR112015023753A2 (pt) | composições, formulações e métodos para o tratamento de doenças oculares | |
CL2012003415A1 (es) | Compuestos derivados de 2-oxo-piperidina y 1,1-dioxido-tiazina, inhibidores de mdm2; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer . | |
CY1118731T1 (el) | Φαρμακευτικες συνθεσεις αλβιγλουτιδης | |
CY1119007T1 (el) | Συνθεσεις και μεθοδοι αγωγης πνευμονικης υπερτασης | |
SV2015005115A (es) | Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades | |
GT200900283A (es) | "terapia de combinación con un compuesto actuando como un inhibidor del receptor adp plaquetario". | |
CL2015001358A1 (es) | Potenciadores del cftr deuterados | |
CL2011002942A1 (es) | Compuestos derivados de 2,4-diamino-pirimidina, agonistas de receptor tipo toll-7 (tlr7); composicion farmaceutica; y su uso para el tratamiento del cancer. | |
CL2013000713A1 (es) | Compuestos pirazin-2-cabonil-imino-1,3,8-triaza-espiro-[4.5]-decan-sustituidos, bloqueadores del canal de sodio epitelial (enac); composicion farmaceutica que los incluye; metodo de prevencion o tratamiento; y su uso para tratar una enfermedad o condicion mediada por el bloqueo del canal de sodio epitelial. | |
UY30846A1 (es) | Derivados de oxindol sustituidos, medicamentos que los comprenden y uso de los mismos | |
CL2011000101A1 (es) | Compuestos derivados de piridazina sustituida; inhibidores de la señalizacion hedgehog y smo; composicion farmaceutica; y uso para el tratamiento de trastornos o sindromes asociados con enfermedades hiperproliferativas. | |
NI201000105A (es) | Régimen de dosificación asociado con ésteres de paliperidona inyectables de acción prolongada. | |
CL2008001705A1 (es) | Compuestos derivados de heterociclos de nitrogeno; y uso del compuesto para el tratamiento de enfermedades o trastornos relacionados con el receptor de histamina h3. | |
CL2013001141A1 (es) | Compuestos derivados de heterociclos condensados, inhibidores del virus de la hepatitis c; composicion farmaceutica que los contiene; y su uso para el tratamiento de la infeccion por el virus de la hepatitis c. | |
CO6491060A2 (es) | Compuestos y composiciones para el tratamiento de enfermedades parasitarias | |
CY1121554T1 (el) | Παραγωγο πυρανοχρωμενυλ-φαινολης, και φαρμακευτικη συνθεση για αγωγη μεταβολικου συνδρομου ή φλεγμονωδους παθησης |